OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	299
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	237
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	145
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	122
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	113
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	95
Correction	84
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	78
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	77
In silico prediction of post-translational modifications in therapeutic antibodies	69
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	68
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	67
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	63
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	62
Correction	62
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	53
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	49
An antibody developability triaging pipeline exploiting protein language models	47
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	47
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	46
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	43
Correction	43
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	41
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	40
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	38

Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	38
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	37
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	37
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	37
Structural and functional characterization of a monoclonal antibody blocking TIGIT	35
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	35
Impact of IgG subclass on monoclonal antibody developability	33
Antibodies to watch in 2024	32
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	32
Predicting antibody binders and generating synthetic antibodies using deep learning	32
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	32